Impact of Roux-en-Y gastric bypass on regulation of diabetes type 2 in morbidly obese patients

被引:14
作者
Proczko-Markuszewska, Monika [1 ]
Stefaniak, Tomasz [1 ]
Kaska, Lukasz [1 ]
Kobiela, Jarek [1 ]
Sledzinski, Zbigniew [1 ]
机构
[1] Med Univ Gdansk, Dept Gen Endocrine & Transplant Surg, PL-80952 Gdansk, Poland
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2012年 / 26卷 / 08期
关键词
Diabetes mellitus type 2; Metabolic surgery; Roux-en-Y gastric bypass; Incretins; BARIATRIC SURGERY; METABOLIC SURGERY; MELLITUS; INCRETINS; WEIGHT; MECHANISMS; RESOLUTION; THERAPY; DISEASE; KG/M(2);
D O I
10.1007/s00464-012-2160-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
The idea of surgery as treatment for type 2 diabetes mellitus (T2DM) was established in the US and was based on observation of patients after bariatric surgery. Resolution of T2DM is observed within a few weeks after surgery, in some cases even during hospitalization. The aim of this study was to evaluate the impact of Roux-en-Y gastric bypass (RYGB) on diabetes in morbidly obese patients. We present 73 patients with T2DM who underwent laparoscopic RYGB (LRYGB) to treat morbid obesity. In the group of 73 obese patients (mean BMI = 42.3), there were 41 females and 32 males. Regression of T2DM was observed in 51 patients (69.8%) while hospitalized. In addition, 14 patients' (19.1%) glycemia and HBA1c stabilized within 12 weeks after surgery (total regression rate of 88.9%). The ultimate evaluation of this method of treating T2DM is still lacking and requires several years of meticulous clinical studies. Despite that, considering the high cost of life-long conservative therapy of T2DM and its complications and the severe impact T2DM has on quality of life, surgical metabolic intervention may become the most reasonable solution in many cases.
引用
收藏
页码:2202 / 2207
页数:6
相关论文
共 32 条
[1]  
Amer Diabet Assoc, 2012, DIABETES CARE, V35, pS64, DOI [10.2337/dc19-S002, 10.2337/dc12-S064, 10.2337/dc23-S002, 10.2337/dc09-S062, 10.2337/dc18-S002]
[2]  
[Anonymous], 2008, NIH PUBL
[3]  
[Anonymous], 2009, DIAB ATL
[4]  
[Anonymous], 2010, 9 M SURG CONT ED 14
[5]   Cardiovascular risk after bariatric surgery for obesity [J].
Batsis, John A. ;
Sarr, Michael G. ;
Collazo-Clavell, Maria L. ;
Thomas, Randal J. ;
Romero-Corral, Abel ;
Somers, Virend K. ;
Lopez-Jimenez, Francisco .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (07) :930-937
[6]   Do Incretins Play a Role in the Remission of Type 2 Diabetes after Gastric Bypass Surgery: What are the Evidence? [J].
Bose, Mousumi ;
Olivan, Blanca ;
Teixeira, Julio ;
Pi-Sunyer, F. Xavier ;
Laferrere, Blandine .
OBESITY SURGERY, 2009, 19 (02) :217-229
[7]   Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis [J].
Buchwald, Henry ;
Estok, Rhonda ;
Fahrbach, Kyle ;
Banel, Deirdre ;
Jensen, Michael D. ;
Pories, Walter J. ;
Bantle, John P. ;
Sledge, Isabella .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (03) :248-U81
[8]   Bariatric surgery reduces cancer risk in morbidly obese patients [J].
Christou, Nicolas V. ;
Lieberman, Moishe ;
Sampalis, Fotini ;
Sampalis, John S. .
SURGERY FOR OBESITY AND RELATED DISEASES, 2008, 4 (06) :691-695
[9]   End-to-side Duodeno-jejunostomy with half-and-half biliopancreatic limb for the treatment of type 2 diabetes: A proposal for a simpler technique [J].
Dallegrave Marchesini, Joao Caetano .
OBESITY SURGERY, 2007, 17 (01) :138-139
[10]   Metabolic Surgery for the Treatment of Type 2 Diabetes in Patients with BMI <35 kg/m2: An Integrative Review of Early Studies [J].
Fried, M. ;
Ribaric, G. ;
Buchwald, J. N. ;
Svacina, S. ;
Dolezalova, K. ;
Scopinaro, N. .
OBESITY SURGERY, 2010, 20 (06) :776-790